AAD 2018

AAD insights and takeawaysIn this article, Dr. Norman Levine sums up his takeaways from the American Academy of Dermatology annual meeting, beginning with a presentation by two physicians who addressed the difficulties of managing hidradenitis suppurativa, such as fixed dosing. He also addressed controversies associated with treatments for atopic dermatitis. Apparently, bleach baths are no better than regular baths in improving skin symptoms.
Laddered treatment for pityriasis rubra pilarisDiagnosing PRP is challenging because it can mimic eczema, psoriasis, or even ichthyosis. Biologic treatment for refractory cases considered, researchers said at AAD 2018.
Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidityInitial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
From new vaccines to the advent of new neurotoxinsPhysicians weigh in expectations for new developments within all facets of dermatology from pediatric dermatology to dermatopathology.
Managing hedgehog therapies for basal cell carcinomaWhile the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Biologics offer promise for hidradenitis suppurativa treatmentWith one approved biologic available and many more under investigation, the future of treatment for hidradenitis suppurativa looks very promising.
Up-and-coming fillers and neuromodulatorsInjectable aesthetic products recently FDA-approved or in late stages of development include polycaprolactone, a new hyaluronic acid and multiple neuromodulators.
Transgender dermatology care faces unique challengesThe transgender dermatology patient may face a unique set of challenges doctors should be prepared to address, says Dr. Brian Ginsberg.
Medicare, coding and reimbursement challenges that lie aheadSpeaking at the American Academy of Dermatology annual meeting in February, Dr. Brett Coldiron described challenges dermatologists should be prepared for this year, including Medicare payment reductions, insurers' cost-saving strategies and practice consolidations.
Switching biologic treatments in dermatologyNot all biologic treatments are equal. Side effects, effectiveness, cost and administration style are among factors physicians should consider when switching treatments, experts report at AAD 2018.